The Southeast Cancer Control Consortium, Inc., (SCCC) is a Community Clinical Oncology Program (CCOP) funded for the past 12 years by the National Cancer Institute (NCI). The SCCC is a consortium of 15 communities and 16 institutions in a five-state area of the southeast United States. The SCCC's long term objective is to bring state of the art clinical trials and prevention programs for cancer to an arena of small community institutions, to increase access to NCI approved cancer programs. The catchment of the referral communities is estimated at 8.5 million, with demographics reflecting a low population density, limited socioeconomic and educational development, and an African American to white population approximately twice the national average. This provides an opportunity to increase minority access to research studies. There are 104 physicians (medical oncologists, surgeons, radiation oncologists, and urologists) participating in the SCCC. Each institution has a physician designated as the """"""""Community Leader,"""""""" responsible for locally coordinating participation in the SCCC program. Each Community Leader has a support team of personnel [oncology nurses and clinical research associates (CRAs)] who are trained, by the SCCC Operations Office staff, in proper procedures for compliance to federal and research base regulations. The community support teams' efforts are coordinated and monitored by the Community Leaders' counterpart, an oncology nurse or CRA, who is the local """"""""Study Coordinator."""""""" The SCCC Operations Office coordinates the consortium's activities by providing a telephone and e-mail information service line for members' questions, monitoring Institutional Review Board (IRB) approvals, facilitating protocol participation via weekly mailings, conducting on-site visits, providing data management training and continuing education programs, preparing grant applications and reports, and coordinating research base audits. The SCCC Operations Office provides the communities with research studies, for both cancer treatment and prevention, from five national cooperative group research bases approved by NCI. Plans are in progress for adding a sixth research base. Each community then has these studies reviewed by their local IRB, all of which are approved by the Office for Protection from Research Risks (OPRR). The Community Leaders and Study Coordinators then educate local members and facilitate implementation of these studies within the community. Through the expansive consortium network, we are confident that our program will significantly improve the quality of and access to NCI approved state of the art cancer care and prevention studies in the community setting. We will be able to reduce the morbidity and mortality of cancer by overcoming ethnic, minority, and socioeconomic barriers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045808-18
Application #
6773157
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
Whitman, Cynthia B
Project Start
1987-07-01
Project End
2005-05-31
Budget Start
2004-08-27
Budget End
2005-05-31
Support Year
18
Fiscal Year
2004
Total Cost
$1,898,488
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9

Showing the most recent 10 out of 215 publications